BFM
CUE icon

Boothbay Fund Management’s Cue Biopharma CUE Stock Holding History

Boothbay Fund Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,477
Closed -$215K – 2146
2025
Q4 		$215K Buy
23,477
+3,112
+15% +$57.2K ﹤0.01% 1631
2025
Q3 		$439K Buy
+20,365
New +$478K 0.01% 1241
2022
Q3 		– Sell
-412
Closed -$31K – 2302
2022
Q2 		$31K Buy
+412
New +$48.2K ﹤0.01% 2158

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

Boothbay Fund Management's CUE Position: Q1 2026 in Review

Boothbay Fund Management sold out of Cue Biopharma (CUE) in Q1 2026, closing a stake of 23,477 shares — an estimated $215K sold.

Boothbay Fund Management first reported a position in CUE in Q2 2022 and held it in 3 quarters. The position peaked at $439K in Q3 2025. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Boothbay Fund Management reported no remaining Cue Biopharma position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 23,477 Cue Biopharma shares in Q1 2026, an estimated $215K.
  • Boothbay Fund Management first reported a position in Cue Biopharma in Q2 2022 and held it in 3 quarters.
  • Boothbay Fund Management's Cue Biopharma position peaked at $439K in Q3 2025.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.